Rouble climbs to near two-week high as Ukraine pummels Moscow with drones
The Russian rouble strengthened to a near two-week high against the dollar on Tuesday, buoyed by subdued imports and hopes for a resolution to the war in Ukraine, even as Kyiv launched its biggest drone attack on Moscow.
Ukraine's attack, which saw at least 91 drones target the Russian capital, sparked fires, closed airports and forced dozens of flights to be diverted, Russian officials said.
By 0807 GMT, the rouble was up 0.9% at 86.80 to the dollar in over-the-counter market trade, its strongest level since February 27. Against the Chinese yuan, the most traded foreign currency in Russia, the rouble was down 0.1% to 11.89.
The rouble is up against the dollar this year, mostly thanks to expectations of improved relations between Moscow and Washington that could produce some conflict resolution in Ukraine and the possible easing of sanctions against Russia.
The rouble brushed aside U.S. President Donald Trump's threat last week of imposing banking sanctions on Russia to force it to the negotiating table and was unmoved by Ukraine's drone bombardment on Tuesday.
Strong exports, subdued imports and the geopolitical risk premium is keeping the national currency from devaluation, said BCS World of Investments analysts.
"The national currency's exchange rate can only devalue if negotiations are disrupted without prospects for their resumption, but this is not the baseline scenario," they said.
Brent crude oil, a global benchmark for Russia's main export, was up 0.3% at $69.49 a barrel.
(Reporting by Alexander Marrow, Editing by Louise Heavens)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Channel Post MEA
an hour ago
- Channel Post MEA
Khazna Data Centres And NVIDIA To Build AI Large Data Centres Across MEA
Khazna Data Centers (Khazna) has announced it is collaborating with NVIDIA to build AI factories in the MEA region. Following the high-profile visit of U.S. President Donald Trump to the UAE, and the announcement of a planned 5GW UAE-US AI campus, the collaboration is another example of the deepening ties between the region and U.S. technology leaders in shaping the future of AI and digital infrastructure. Through this collaboration, NVIDIA has certified the design of Khazna's next-generation facilities to support the NVIDIA Blackwell architecture. Khazna's ongoing and upcoming infrastructure developments will feature NVIDIA-ready blueprints as standard, ensuring full compatibility with the latest GPU-accelerated workloads. Khazna will design the majority of its future data halls with capacities of up to 50MW, developing individual AI clusters of up to 250MW. With many of these data halls situated in the planned UAE-US AI campus, this will place the UAE among the world's most advanced AI infrastructure hubs. Khazna is also expanding rapidly across the Middle East, Africa and Europe, with plans to scale up to 1GW of capacity in countries such as France, Italy, Saudi Arabia, Egypt, Türkiye, and Kenya. 'The world is entering a new era of AI-driven innovation, and the UAE is uniquely positioned to lead. Our work with NVIDIA represents a bold step forward in delivering high-performance, future-ready infrastructure at unprecedented scale. It reinforces our support for the UAE's ambitions to become a global AI leader,' said Hassan Alnaqbi, CEO of Khazna Data Centers.
Arabian Post
2 hours ago
- Arabian Post
MediLink Therapeutics Taps Major Banks for Hong Kong Float
MediLink Therapeutics Ltd. is preparing to launch an initial public offering in Hong Kong, having secured China International Capital Corp., JPMorgan Chase & Co. and Morgan Stanley as its lead advisers, according to people with knowledge of the matter. The move comes as the clinical-stage biotech firm seeks to capitalise on growing investor interest in advanced tumour-targeting therapies and consolidate its platform of antibody‑drug conjugates. Founded in 2020 and headquartered in Suzhou with R&D operations in Shanghai and Boston, MediLink has developed a proprietary ADC technology known as TMALIN®. The platform facilitates precise delivery of cytotoxic agents to tumour cells, with the intention of widening therapeutic windows for solid tumour treatments. Its pipeline includes programs that have advanced to clinical stages in both China and the United States, supported by a Series B financing round of approximately USD 70 million in 2022. MediLink's strategic engagement of three underwriters reflects heightened confidence in anchor investors and broader syndication. China International Capital Corp. brings deep roots in Chinese capital markets and extensive IPO experience in the biotech sector. JPMorgan and Morgan Stanley add global banking heft and access to international investors. ADVERTISEMENT CICC itself is emerging as a top-tier sponsor for Hong Kong listings. It led or co-led 19 IPOs for Chinese corporates last year, raising USD 3.84 billion, positioning it as a dominant force amid market revival. The engagement of internationally renowned banks alongside CICC is likely aimed at boosting MediLink's valuation and widening investor interest both locally and abroad. While IPO details remain confidential, analysts suggest MediLink could seek a valuation in the mid‑to‑high hundreds of millions of dollars. That would reflect both the advanced stage of its pipeline and prevailing market multiples for ADC developers. Comparable biotech flotations in Hong Kong and the U.S. have reflected growing appetite for oncology-focused platforms. Alongside listing ambitions, MediLink continues to advance its clinical and licensing goals. In March it unveiled preclinical data at the American Association for Cancer Research annual meeting; earlier in the year it received FDA clearance for its IND application for YL217, its lead candidate. YL201, another programme, received Breakthrough Therapy Designation in January for treatment of recurrent/metastatic nasopharyngeal carcinoma. The company has also pursued strategic licensing agreements with global pharmaceutical firms to expand development and commercialisation capabilities. A licensing deal under discussion ahead of the IPO is believed aimed at enhancing distribution reach while reinforcing MediLink's balance sheet. The IPO effort is part of a broader resurgence in biotech listings in Hong Kong, where authorities have eased regulations to attract innovation-driven offerings. CICC and other banks have ramped up support for ADC and gene therapy companies, signalling a turning point after a lull in listings. ADVERTISEMENT MediLink's choice of banks aligns with a wider trend: CICC has co-sponsored blockbuster floats including the forthcoming mega‑IPO of CATL, while banks like Goldman Sachs and Morgan Stanley have also participated. In this context, MediLink is positioning itself to tap both deep domestic networks and international capital. Stakeholder sentiment appears optimistic. MediLink's management team, comprised of co‑founders Tony Xue and Jiaqiang Cai alongside C‑suite leaders experienced in drug development and financial strategy, has overseen steady progress in its ADC pipeline and established global partnerships. Jason Li's appointment as CFO in 2023 reportedly strengthened the company's capital market readiness. Market observers highlight challenges ahead. ADC development remains capital-intensive, clinical risks high, and competition fierce among domestic and international peers. Success will hinge on late‑stage data and licensing traction. At the same time, geopolitical tensions and volatility in Hong Kong equity markets may affect investor sentiment. MediLink must also navigate post‑IPO obligations, including regulatory reporting and corporate governance under Hong Kong's Main Board requirements. Mitigating execution risk will be critical, underscoring the role of its chosen bankers in underwriting diligence and market support. Analysts describe the listing as a pivotal moment: it offers the backing to fund Phase II/III efforts while elevating MediLink's corporate profile. For banks, it reinforces Hong Kong's appeal as a biotech capital market when compared with established centres like Nasdaq. With its IPO process underway, MediLink now awaits market timing and regulatory clearances before formally filing a prospectus. The company is expected to continue advancing clinical data, strengthening licensing ties, and preparing investor materials aligned with regulatory requirements.
Zawya
2 hours ago
- Zawya
UAE's Khazna, NVIDIA partner to build AI-capable mega data centres across MEA
UAE-headquartered Khazna Data Centres (Khazna) announced on Wednesday a strategic collaboration with US-based chipmaker NVIDIA to develop large-scale data centres ready for artificial intelligence (AI) workloads across the Middle East and Africa (MEA) region. The company said that its current and future projects will be designed to be full compatible with the NVIDIA's latest GPU-accelerated technologies and workloads NVIDIA has certified Khazna's upcoming facility designs to support its latest GPU architecture Blackwell. As part of its expansion strategy, Khazna will develop data halls with individual capacities of up to 50 megawatts (MW), and AI clusters of up to 250MW each. Many of these will be housed within the planned 5-gigawatt (GW) UAE-US AI campus announced during the recent visit of U.S. President Donald Trump to the UAE. Khazna said it plans to reach 1 GW of capacity with data centre projects in France, Italy, Saudi Arabia, Egypt, Türkiye, and Kenya. 'Our work with NVIDIA represents a bold step forward in delivering high-performance, future-ready infrastructure at unprecedented scale,' said Hassan Alnaqbi, CEO of Khazna Data Centres. 'It reinforces our support for the UAE's ambitions to become a global AI leader.' (Writing by SA Kader; Editing by Anoop Menon)
